Latest filing published 01 Mar 2021 for Adma Biologics, INC..
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 9 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -47.3%Entry US$2.24 · Close at T+365 US$1.18
- -50.8%Entry US$3.03 · Close at T+365 US$1.49
- -19.3%Entry US$3.58 · Close at T+365 US$2.89
- -38.1%Entry US$4.70 · Close at T+365 US$2.91
- +82.2%Entry US$2.75 · Close at T+365 US$5.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
James Mond: trading record in brief
This profile gathers the share dealings of James Mond in Adma Biologics, Inc. The record holds 11 filings, for trades running from 14 May 2014 to 25 February 2021.
The open-market record is one-sided, with 9 purchases worth €94k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants.
The median purchase comes to €9,564. On 7 out of 7 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Looking at 9 purchases old enough to measure, the stock rose over the following 90 days in 33% of cases; the median change was -5.8%. These figures describe past trades and do not predict future prices.
The newest entry dates from 1 March 2021: a share grant, in Adma Biologics, Inc. The last purchase on record was published on 10 September 2020, which is 2,251 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to James Mond
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 64,361 shares0Common StockSEC:0001193805-21-000292:0
- 4,000 shares@ US$2.2019.5% of flowCommon StockSEC:0001193805-20-001129:0Canonical exit: 7 Dec 2020 (T+90)
- 5,000 shares@ US$2.8832.0% of flowCommon StockSEC:0001193805-20-001003:0Canonical exit: 8 Nov 2020 (T+90)
- 2,000 shares@ US$2.8812.8% of flowCommon StockSEC:0001193805-20-001003:1Canonical exit: 8 Nov 2020 (T+90)
- 40,000 shares0Common StockSEC:0001193805-20-000285:0
- 4,285 shares@ US$3.5035.8% of flowCommon StockSEC:0001193805-20-000133:0Canonical exit: 11 May 2020 (T+90)
- 4,500 shares@ US$4.0029.6% of flowCommon StockSEC:0001193805-19-000522:0Canonical exit: 15 Aug 2019 (T+90)
- 10,000 shares@ US$2.1524.0% of flowCommon StockSEC:0001193805-17-003449:0Canonical exit: 7 Feb 2018 (T+90)
- 770 shares@ US$6.505.6% of flowCommon Stock, $0.0001 par value per shareSEC:0001193805-16-003193:0Canonical exit: 1 Aug 2016 (T+90)
- 1,250 shares@ US$8.02Common Stock, $0.0001 par value per shareSEC:0001193805-15-000401:0Canonical exit: 14 Jun 2015 (T+90)
- 1,315 shares@ US$7.60Common Stock, $0.0001 par value per shareSEC:0001193805-14-001044:0Canonical exit: 12 Aug 2014 (T+90)
11 of 11 declarations
